TG Therapeutics Inc (TGTX : NASDAQ)
Common Stock
$55.85
USD
+0.00 (%)
Last updated: 2026-09-17
Get TGTX alerts:
TGTX
TG Therapeutics Inc
WealthAwesomePerformance
1 Day
+5.30%
1 Week
+2.20%
1 Month
+13.33%
YTD
+8.45%
Key Statistics
Market Cap
$8.55B
52W High
$59.30
52W Low
$26.76
P/E Ratio
19.39
50 Day MA
$53.51
200 Day MA
$39.82
Beta
1.66
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $57.61 | $57.87 | $56.04 | $56.47 | $56.47 | 1,467,870 |
| 9/16/2026 | $53.12 | $57.60 | $53.10 | $55.85 | $55.85 | 2,349,579 |
| 9/15/2026 | $53.59 | $54.41 | $52.50 | $53.04 | $53.04 | 1,758,959 |
| 9/14/2026 | $53.97 | $54.20 | $53.19 | $54.00 | $54.00 | 1,362,263 |
| 9/11/2026 | $55.71 | $56.26 | $53.47 | $53.89 | $53.89 | 1,368,582 |
| 9/10/2026 | $54.36 | $55.41 | $54.01 | $55.39 | $55.39 | 1,367,400 |
| 9/9/2026 | $55.55 | $57.14 | $54.24 | $54.65 | $54.65 | 1,409,800 |
| 9/8/2026 | $55.34 | $55.92 | $54.09 | $55.74 | $55.74 | 1,085,500 |
| 9/4/2026 | $56.30 | $56.70 | $55.56 | $55.98 | $55.98 | 992,400 |
| 9/3/2026 | $57.40 | $58.47 | $56.19 | $56.71 | $56.71 | 1,571,300 |
Analyst Price Targets
Based on 9 analysts covering TGTX · as of Sep 17, 2026
Wall Street analysts forecast TGTX stock price to rise 24.8% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
US$69.71
+24.8% Upside
Current Price
US$55.85
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TGTX's historical volatility
30-Day Vol
37.7%
Annualized
90-Day Vol
46.4%
Annualized
Trend (90d)
+19.3%
Annualized drift
90d Mean
US$60.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$57.78 | US$50.72 – US$65.82 |
| 60 trading days | US$59.12 | US$49.17 – US$71.08 |
| 90 trading days | US$60.49 | US$48.27 – US$75.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Financials
- Revenue (TTM)
- $799.54M
- EBITDA
- $136.45M
- Profit Margin
- 55.22%
- ROE (TTM)
- 100.28%
- EPS (Diluted)
- 2.88
- Book Value
- 4.11
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About TGTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
TGTX.US news timeline
1 article covering TGTX.US, most recent first
Latest